Bionano Genomics (BNGO) 10-Q 4 Nov 21 2021 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2021	Oct. 31, 2021
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2021
Document Transition Report	false
Entity File Number	001-38613
Entity Registrant Name	Bionano Genomics, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	26-1756290
Entity Address, Address Line One	9540 Towne Centre Drive, Suite 100
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92121
City Area Code	858
Local Phone Number	888-7600
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		289,184,109
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Entity Central Index Key	0001411690
Current Fiscal Year End Date	--12-31
Common Stock
Document Information [Line Items]
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	BNGO
Security Exchange Name	NASDAQ
Warrant
Document Information [Line Items]
Title of 12(b) Security	Warrants to purchase Common Stock
Trading Symbol	BNGOW
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 140,736	$ 38,449
Investments	185,333	0
Accounts receivable, net of allowance for doubtful accounts of, 2,015,000 and 2,119,000 as of September 30, 2021 and December 31, 2020, respectively	2,996	2,775
Inventory, net	9,020	3,316
Prepaid expenses and other current assets	3,962	2,250
Total current assets	342,047	46,790
Property and equipment, net	8,554	4,910
Intangible assets, net	1,238	1,475
Goodwill	7,173	7,173
Other long-term assets	645	103
Total assets	359,657	60,451
Current liabilities:
Accounts payable	7,875	2,930
Accrued expenses	9,416	5,599
Contract liabilities	411	416
Total current liabilities	17,702	8,945
Long-term debt	0	16,326
Long-term contract liabilities	158	98
Other non-current liabilities	232	0
Total liabilities	18,092	25,369
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of September 30, 2021 and December 31, 2020	0	0
Common stock, $0.0001 par value, 400,000,000 shares authorized at September 30, 2021 and December 31, 2020; 281,441,000 and 189,953,000 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively	28	19
Additional paid-in capital	534,823	178,747
Accumulated deficit	(193,170)	(143,684)
Accumulated other comprehensive loss	(116)	0
Total stockholders’ equity	341,565	35,082
Total liabilities and stockholders’ equity	$ 359,657	$ 60,451

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 2,015	$ 2,119
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in USD per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	400,000,000	400,000,000
Common stock, shares issued (in shares)	281,441,000	189,953,000
Common stock, shares outstanding (in shares)	281,441,000	189,953,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenue:
Total revenue	$ 4,655	$ 2,196	$ 11,679	$ 4,513
Cost of revenue:
Total cost of revenue	3,501	1,460	8,044	2,919
Operating expenses:
Research and development	6,505	2,304	13,270	7,379
Selling, general and administrative	15,327	8,659	38,683	21,640
Total operating expenses	21,832	10,963	51,953	29,019
Loss from operations	(20,678)	(10,227)	(48,318)	(27,425)
Other income (expense):
Interest income (expense)	27	(589)	(721)	(1,911)
Gain on forgiveness of PPP Loan	0	0	1,775	0
Loss on debt extinguishment	0	0	(2,076)	0
Other income (expense)	(67)	54	(96)	0
Total other income (expense)	(40)	(535)	(1,118)	(1,911)
Loss before income taxes	(20,718)	(10,762)	(49,436)	(29,336)
Provision for income taxes	(35)	(30)	(50)	(40)
Net loss	$ (20,753)	$ (10,792)	$ (49,486)	$ (29,376)
Net loss per share, basic (in dollars per share)	$ (0.07)	$ (0.08)	$ (0.18)	$ (0.34)
Net loss per share, diluted (in dollars per share)	$ (0.07)	$ (0.08)	$ (0.18)	$ (0.34)
Weighted-average common shares outstanding, basic (in shares)	280,173	132,942	274,392	86,632
Weighted-average common shares outstanding, diluted (in shares)	280,173	132,942	274,392	86,632
Product revenue
Revenue:
Total revenue	$ 3,300	$ 1,580	$ 7,845	$ 3,503
Cost of revenue:
Total cost of revenue	2,340	1,136	5,723	2,426
Service and other revenue
Revenue:
Total revenue	1,355	616	3,834	1,010
Cost of revenue:
Total cost of revenue	$ 1,161	$ 324	$ 2,321	$ 493

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (Statement) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Statement of Comprehensive Income [Abstract]
Net Loss	$ (20,753)	$ (10,792)	$ (49,486)	$ (29,376)
Unrealized (loss) on investment securities	(116)	0	(116)	0
Comprehensive Loss	$ (20,869)	$ (10,792)	$ (49,602)	$ (29,376)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders’ Equity (Deficit) (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss
Beginning Balance (in shares) at Dec. 31, 2019		34,274
Beginning Balance at Dec. 31, 2019	$ 3,614	$ 3	$ 106,188	$ (102,577)
Equity
Stock-based compensation expense	328		328
Issue stock for warrant exercises (in shares)		3,478
Issue stock for warrant exercises	2,355		2,355
Net loss	(10,510)			(10,510)
Ending Balance (in shares) at Mar. 31, 2020		37,752
Ending Balance at Mar. 31, 2020	(4,213)	$ 3	108,871	(113,087)
Beginning Balance (in shares) at Dec. 31, 2019		34,274
Beginning Balance at Dec. 31, 2019	3,614	$ 3	106,188	(102,577)
Equity
Net loss	(29,376)
Comprehensive Loss	0
Ending Balance (in shares) at Sep. 30, 2020		148,348
Ending Balance at Sep. 30, 2020	14,676	$ 15	146,614	(131,953)
Beginning Balance (in shares) at Mar. 31, 2020		37,752
Beginning Balance at Mar. 31, 2020	(4,213)	$ 3	108,871	(113,087)
Equity
Stock-based compensation expense	328		328
Issue common stock, net of issuance costs (in shares)		16,896
Issue common stock, net of issuance costs	16,366	$ 2	16,364
Issue stock for employee stock purchase plan (in shares)		44
Issue stock for employee stock purchase plan	21		21
Issue stock for covenant waiver (in shares)		873
Issue stock for covenant waiver	300		300
Issue stock for warrant exercises (in shares)		36,410
Issue stock for warrant exercises	1,109	$ 4	1,105
Net loss	(8,074)			(8,074)
Ending Balance (in shares) at Jun. 30, 2020		91,975
Ending Balance at Jun. 30, 2020	5,837	$ 9	126,989	(121,161)
Equity
Stock-based compensation expense	447		447
Issue stock for warrant exercises (in shares)		50,205
Issue stock for warrant exercises	15,083	$ 5	15,078
Issue stock for acquisition (in shares)		6,168
Issue stock for acquisition	4,101	$ 1	4,100
Net loss	(10,792)			(10,792)
Comprehensive Loss	0
Ending Balance (in shares) at Sep. 30, 2020		148,348
Ending Balance at Sep. 30, 2020	14,676	$ 15	146,614	(131,953)
Beginning Balance (in shares) at Dec. 31, 2020		189,953
Beginning Balance at Dec. 31, 2020	35,082	$ 19	178,747	(143,684)
Equity
Stock option exercises (in shares)		102
Stock option exercises	333		333
Stock-based compensation expense	371		371
Issue common stock, net of issuance costs (in shares)		78,000
Issue common stock, net of issuance costs	327,486	$ 8	327,478
Issue stock for warrant exercises (in shares)		10,739
Issue stock for warrant exercises	9,393	$ 1	9,392
Net loss	(9,947)			(9,947)
Ending Balance (in shares) at Mar. 31, 2021		278,794
Ending Balance at Mar. 31, 2021	362,718	$ 28	516,321	(153,631)
Beginning Balance (in shares) at Dec. 31, 2020		189,953
Beginning Balance at Dec. 31, 2020	$ 35,082	$ 19	178,747	(143,684)
Equity
Stock option exercises (in shares)	371
Net loss	$ (49,486)
Comprehensive Loss	(116)
Ending Balance (in shares) at Sep. 30, 2021		281,441
Ending Balance at Sep. 30, 2021	341,565	$ 28	534,823	(193,170)	$ (116)
Beginning Balance (in shares) at Mar. 31, 2021		278,794
Beginning Balance at Mar. 31, 2021	362,718	$ 28	516,321	(153,631)
Equity
Stock option exercises (in shares)		60
Stock option exercises	89		89
Stock-based compensation expense	1,758		1,758
Issue stock for employee stock purchase plan (in shares)		150
Issue stock for employee stock purchase plan	65		65
Issue stock for warrant exercises (in shares)		50
Issue stock for warrant exercises	22		22
Net loss	(18,786)			(18,786)
Ending Balance (in shares) at Jun. 30, 2021		279,054
Ending Balance at Jun. 30, 2021	345,866	$ 28	518,255	(172,417)
Equity
Stock option exercises (in shares)		209
Stock option exercises	242		242
Stock-based compensation expense	2,788		2,788
Issue common stock, net of issuance costs (in shares)		2,178
Issue common stock, net of issuance costs	13,537		13,537
Issue stock for warrant exercises	1		1
Net loss	(20,753)			(20,753)
Comprehensive Loss	(116)				(116)
Ending Balance (in shares) at Sep. 30, 2021		281,441
Ending Balance at Sep. 30, 2021	$ 341,565	$ 28	$ 534,823	$ (193,170)	$ (116)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Operating activities:
Net loss	$ (49,486)	$ (29,376)
Adjustments to reconcile net loss to net cash used by operating activities:
Depreciation and amortization expense	1,490	909
Non-cash interest	178	952
Stock-based compensation	4,917	1,103
Provision for bad debt expense	0	1,334
Gain on forgiveness of PPP Loan	(1,775)	0
Loss on debt extinguishment	2,076	0
Changes in operating assets and liabilities:
Accounts receivable	(336)	1,709
Inventory	(10,346)	(3,612)
Prepaid expenses and other current assets	(2,072)	(566)
Accounts payable	4,945	925
Accrued expenses and contract liabilities	4,104	412
Net cash used in operating activities	(46,305)	(26,210)
Investing Activities:
Lineagen acquisition, net of cash acquired	0	(2,450)
Purchases of property and equipment	(344)	0
Purchase of available for sale securities	(205,334)	0
Sale of available for sale securities	20,000	0
Sale of property and equipment	126	0
Net cash used in investing activities	(185,552)	(2,450)
Financing activities:
Repayment of term-loan debt	(17,010)	(5,000)
Proceeds from PPP Loan	0	1,775
Proceeds from borrowing from line of credit	0	761
Repayments of borrowing from line of credit	0	(2,258)
Proceeds from sale of common stock	342,712	17,963
Offering expenses on sale of common stock	(1,704)	(1,597)
Proceeds from sale of common stock under employee stock purchase plan	65	21
Proceeds from warrant and option exercises	10,081	18,551
Net cash provided by financing activities	334,144	30,216
Net increase in cash and cash equivalents	102,287	1,556
Cash and cash equivalents at beginning of period	38,449	17,311
Cash and cash equivalents at end of period	140,736	18,867
Supplemental cash flow disclosures:
Cash paid for interest	490	991
Supplemental disclosure of non-cash investing and financing activities:
Fair value of common stock issued related to Lineagen acquisition	0	4,100
Transfer of instruments and servers from property and equipment into inventory	544	134
Transfer of instruments and servers from inventory to property and equipment	5,074	2,618
Gain on forgiveness of PPP Loan	1,775	0
Stock issued for services	15	0
Issue common stock for covenant waiver	116	300
Warrant exercise pursuant to cashless exercise	$ 129	$ 0

Organization and Basis of Prese

Organization and Basis of Presentation	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	Organization and Basis of Presentation Description of Business Bionano Genomics, Inc. (collectively, with its consolidated subsidiaries, the “Company”) is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through optical genome mapping (“OGM”) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen, Inc. (“Lineagen”) business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery, Inc. (“BioDiscovery”) business, the Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. Basis of Presentation The accompanying financial information has been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim reporting purposes. The condensed consolidated financial statements are unaudited. The unaudited condensed consolidated financial statements reflect, in the opinion of the Company’s management, all adjustments, consisting of only normal recurring adjustments, necessary for a fair presentation of financial position, results of operations, changes in equity, and comprehensive loss and cash flows for each period presented in accordance with United States generally accepted accounting principles (“U.S. GAAP”). All intercompany transactions and balances have been eliminated. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. Liquidity As of September 30, 2021, the Company had approximately $140.7 million in cash and cash equivalents, $185.3 million in available-for-sale investment securities, and working capital of $324.3 million as a result of common stock offerings executed in the quarters ended December 31, 2020, March 31, 2021, and September 30, 2021. In February 2021, we applied for forgiveness of our Paycheck Protection Program Loan of approximately $1.8 million (“the PPP Loan”) , and in March 2021, the PPP Loan, including all accrued interest, was forgiven in full. During the previous quarter ended June 30, 2021, the outstanding term loan with Innovatus (as defined below) was paid in full, including all accrued interest, an end of term fee, and a prepayment fee for a total of $17.0 million. The Company believes its available cash balance will be sufficient to fund operations, obligations as they become due and capital investments for at least the next twelve months. However, the Company expects to continue to incur net losses for the foreseeable future. The Company plans to continue to fund its losses from operations and capital funding needs through a combination of equity offerings, debt financings or other sources, including potential collaborations, licenses and other similar arrangements. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, potentially harming the Company’s business. COVID-19 The Company is subject to additional risks and uncertainties as a result of the continued spread of COVID-19 and uncertain market conditions, which could continue to have a material impact on the Company’s business and financial results. The Company closely monitors and complies with various applicable guidelines and legal requirements in the jurisdictions in which it operates, which may continue to result in reduced business operations in response to new or existing stay-at-home orders, travel restrictions and other social distancing measures. The Company’s manufacturing partners, suppliers, and customers, have implemented similar operational restrictions. Despite reporting an increase in revenue for the three and nine months ended September 30, 2021 when compared to the same period in 2020, the Company believes travel restrictions and overall reduced activity had a continued negative impact on the Company’s third quarter 2021 financial results. Given the continued evolution of the COVID-19 pandemic and the related complexities and uncertainties associated with the additional variants, the future effects of COVID-19 are unknown and the Company’s financial results may continue to be negatively affected in the future. There may be long-term negative effects of the COVID-19 pandemic, even after it has subsided. Specifically, product demand may be reduced due to an economic recession, a decrease in corporate capital expenditures, prolonged unemployment, reduction in consumer confidence, or any similar negative economic condition. These negative effects could have a material impact on the Company’s operations, business, earnings, and liquidity. Significant Accounting Policies During the three and nine months ended September 30, 2021, there were no changes to the Company’s significant accounting policies as described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, other than the accounting policy indicated below. Fair Value Measurements The Company measures certain financial assets and liabilities at fair value on a recurring basis. Fair value is the price the Company would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date. ASC 820, “Fair Value Measurements and Disclosures”, defines and establishes a framework for measuring fair value and expands disclosures about fair value measurements. In accordance with ASC 820, the Company has categorized its financial assets and liabilities, based on the priority of the inputs to the valuation technique, into a three-level fair value hierarchy as set forth below. Level 1 – Assets and liabilities whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market that the company has the ability to access at the measurement date. Level 2 – Assets and liabilities whose values are based on quoted prices for similar attributes in active markets; quoted prices in markets where trading occurs infrequently; and inputs other than quoted prices that are observable, either directly or indirectly, for substantially the full term of the asset or liability. Level 3 – Assets and liabilities whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. If the inputs used to measure the financial instruments fall within different levels of the hierarchy, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument. Investment Securities All investments have been classified as “available-for-sale” and are carried at fair value as determined based upon quoted market prices or pricing models for similar securities at period end. Investments with contractual maturities less than 12 months at the balance sheet date are considered short-term investments. Investments with contractual maturities beyond one year are also classified as short-term due to the Company’s ability to liquidate the investment for use in operations within the next 12 months. Realized gains and losses on investment securities are included in earnings and are derived using the specific identification method for determining the cost of securities sold. The Company has not realized any significant gains or losses on sales of available-for-sale investment securities during any of the periods presented. As all the Company’s investment holdings are in the form of debt securities, unrealized gains and losses that are determined to be temporary in nature are reported as a component of accumulated other comprehensive income (loss). A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the establishment of a new cost basis for the security. Interest income is recognized when earned, as are the amortization of purchase premiums and accretion of purchase discounts on investment securities. Recently Issued But Not Yet Adopted Accounting Pronouncements In February 2015, the FASB issued Accounting Standards Update (“ASU”) 2016-2, Leases (Topic 842) , which amends the accounting guidance for leases and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about leasing arrangements. ASU 2016-2 initially mandated a modified retrospective transition method, however, in July 2018, the FASB issued ASU 2018-11, Leases (Topic 842): Targeted Improvements, which amends ASU 2016-2, permitting entities the option to adopt this standard prospectively with a cumulative-effect adjustment to opening equity in the year of adoption and include required disclosures for prior periods but will not restate prior periods. The Company anticipates implementing the accounting guidance for leases using the alternative method beginning with the annual reporting period ending December 31, 2021 and interim reporting periods in 2022. The Company is in the process of evaluating the impact of adoption of the lease accounting guidance on the consolidated financial statements. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses: Measurement of credit Losses on Financial Instruments (ASU 2016-13) , which amends the impairment model by requiring entities to use a forward looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available-for-sale debt securities. The standard is effective for the company beginning in the first quarter of 2023, with early adoption permitted. The Company is currently evaluating the expected impact of ASU 2016-13 on its financial statements. In May 2021, the FASB issued ASU No. 2021-04, Issuer’s Accounting for Certain Modifications or Exchanges for Freestanding Equity-Classified Written Call Options to clarify the accounting for modifications or exchanges of equity- classified warrants.The standard is effective for fiscal years beginning after December 15, 2021. Early adoption is permitted. The Company is in the process of evaluating the expected impact of ASU 2021-04

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Net Loss Per Share	Net Loss Per Share Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common share equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. The Company’s potentially dilutive securities which include warrants, outstanding stock options, and Restricted Stock Units (“RSUs”) under the Company’s equity incentive plan have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding. Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares): September 30, September 30, Stock options 10,661,000 5,331,000 Warrants 4,361,000 29,709,000 RSUs 820,000 — Total 15,842,000 35,040,000

Revenue Recognition

Revenue Recognition	9 Months Ended
	Sep. 30, 2021
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition Revenue by Source Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Instruments $ 1,468,000 $ 724,000 $ 3,507,000 $ 1,487,000 Consumables 1,832,000 856,000 4,338,000 2,016,000 Total product revenue 3,300,000 1,580,000 7,845,000 3,503,000 Service and other 1,355,000 616,000 3,834,000 1,010,000 Total revenue $ 4,655,000 $ 2,196,000 $ 11,679,000 $ 4,513,000 Revenue by Geographic Location Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 $ % $ % $ % $ % North America $ 2,557,000 55 % $ 874,000 40 % $ 6,419,000 55 % $ 2,388,000 53 % EMEIA 1,234,000 27 % 1,204,000 55 % 3,762,000 32 % 1,908,000 42 % Asia Pacific 864,000 18 % 118,000 5 % 1,498,000 13 % 217,000 5 % Total $ 4,655,000 100 % $ 2,196,000 100 % $ 11,679,000 100 % $ 4,513,000 100 % The table above provides revenue from contracts with customers by source and geographic region (based on the customer’s billing address) on a disaggregated basis. North America consists of the United States and Canada. EMEIA consists of Europe, the Middle East, India and Africa. Asia Pacific includes China, Japan, South Korea, Singapore and Australia. For the three months ended September 30, 2021 and 2020, the United States represented 44.2% and 40.0% of total revenue, respectively. Additionally, for the three months ended September 30, 2021, China and Canada represented 17.9% and 10.8% of total revenue, respectively. For the three months ended September 30, 2020, no countries other than the United States represented greater than 10% of revenue. For the nine months ended September 30, 2021 and 2020, the United States represented 50.0% and 51.0% of total revenue, respectively. No other countries represented greater than 10% of revenue during the nine months ended September 30, 2021 and 2020. Remaining Performance Obligations As of September 30, 2021, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied was $569,000. These remaining performance obligations primarily relate to extended warranty and support and maintenance obligations. The Company expects to recognize approximately 30.7% of this amount as revenue during the remainder of 2021, 49.9% in 2022, and 19.5% in 2023 and thereafter. Warranty revenue is included in Service and other revenue. The Company recognized revenue of $79,000 and $66,000 during the three months ended September 30, 2021 and 2020, respectively, and revenue of $326,000 and $299,000 during the nine months ended September 30, 2021 and 2020, respectively, which was included in the contract liability balance at the end of the previous year.

Balance Sheet Account Details

Balance Sheet Account Details	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance Sheet Account Details	Balance Sheet Account Details Accounts Receivable September 30, December 31, Accounts receivable, net: Accounts receivable, trade $ 5,011,000 $ 4,894,000 Less allowance for doubtful accounts (2,015,000) (2,119,000) $ 2,996,000 $ 2,775,000 The Company extends credit to its customers in the normal course of business. For diagnostic testing services, receivables are based on either contractual rates with third-party payors, plus the amounts expected to be collected for any patient-responsibility portion, or for non-contracted arrangements, using the amounts expected to be collected from third-party payors and/or the patient-customer based on historical collection experience. The Company does not perform credit evaluations and therefore subsequent adjustments to the amount expected to be collected are recorded to revenue. The balance of our Lineagen accounts receivable balance as of September 30, 2021 was $680,000. For optical genome mapping (“OGM”) products and services, credit is extended based upon an evaluation of each customer’s credit history, financial condition, and other factors. Estimates of allowances for doubtful accounts are determined by evaluating individual customer circumstances, historical payment patterns, length of time past due, and economic and other factors. Bad debt expense is recorded as necessary to maintain an appropriate level of allowance for doubtful accounts in selling, general and administrative expense. During the three and nine months ended September 30, 2021, the Company recorded a recovery of bad debt expense of $(10,000) and $(50,000), respectively, which is included in selling, general and administrative expenses. Amounts are charged to the allowance for doubtful accounts when collection efforts have been exhausted and are deemed uncollectible. Concentrations Accounts receivable is subject to concentration risk whenever a customer has a balance that meets or exceeds 10.0% of the Company’s total accounts receivable balance. As of September 30, 2021, no customers met or exceeded 10% of the Company’s total accounts receivable balance. As of December 31, 2020, two customer balances represented 27.4% of the Company’s total accounts receivable balance. Inventory Inventory is stated at the lower of cost or net realizable value, on a first-in, first-out basis. Inventory includes raw materials and finished goods that may be used in the research and development process and such items are expensed as consumed or expired. Provisions for slow-moving, excess, and obsolete inventories are estimated based on product life cycles, historical experience, and usage forecasts. The components of inventories are as follows: September 30, December 31, Inventory: Raw materials $ 1,024,000 $ 2,283,000 Finished goods 7,996,000 1,033,000 $ 9,020,000 $ 3,316,000

Debt

Debt	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Debt	Debt Paycheck Protection Program On April 17, 2020, the Company received the PPP Loan proceeds of approximately $1.8 million pursuant to the Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) administered by the U.S. Small Business Administration (the “SBA”). The PPP Loan accrued interest at a rate of 1.00% per annum, and is subject to the standard terms and conditions applicable to loans administered by the SBA under the CARES Act. In February 2021, the Company applied for forgiveness of the PPP Loan, and in March 2021, the PPP Loan, including all accrued interest, was forgiven in full. A gain on forgiveness of Paycheck Protection Program loan of $1.8 million was recognized during the nine months ended September 30, 2021. Innovatus LSA In March 2019, the Company entered into a Loan and Security Agreement (the “LSA”) by and among Innovatus Life Sciences Lending Fund I, LP, a Delaware limited partnership (“Innovatus”), as collateral agent and the lenders listed on Schedule 1.1 thereto, including East West Bank. The LSA provided a first term loan of $17.5 million, a second term loan of $2.5 million and a third term loan of $5.0 million (collectively, the “Term Loans”) if the Company satisfied certain funding conditions. Interest on the Term Loans is due on the first of each month at a rate of 10.25% per annum in cash or a discounted rate of 7.25% in cash with 3.0% of the 10.25% per annum rate added to the principal of the loan and subject to accruing interest through the end of the interest only payment period, which ends March 1, 2022. At inception, the Company elected to pay interest in cash at a rate of 7.25% per annum and have 3.0% per annum of the interest added back to the outstanding principal. As of May 14, 2021 (the effective date of the loan payoff), the effective interest rate, including debt issuance costs, for the Term Loans was 16.7%. The LSA provided for prepayment fees of 3.0% of the outstanding balance of the loan if the loan is repaid on or prior to March 14, 2020, 2.0% of the amount prepaid if the prepayment occurs after March 14, 2020 but prior to March 14, 2021, 1.0% of the amount prepaid after March 14, 2021 but prior to March 14, 2022 and 0% of the amount prepaid if the prepayment occurs thereafter. In addition, upon the final repayment of the total amounts borrowed, the Company is required to pay an end of term fee of $0.8 million. This end of term fee was being recognized as interest expense over the term of the LSA. As of September 30, 2021, the outstanding term loan with Innovatus was paid in full, including all accrued interest, the end of term fee, and a prepayment fee for a total of $17.0 million. The LSA also provides for a revolving line of credit in an amount not to exceed $5.0 million (the “Revolver”), which was terminated effectively upon payment in full of the above term loan. Summary of Debt Obligations The Company had no debt as of September 30, 2021.The carrying value of the Company’s debt as of December 31, 2020 was as follows: December 31, Term Loans $ 15,981,000 PPP Loan 1,775,000 Total principal 17,756,000 Less unamortized debt issuance costs (1,430,000) Total carrying value of debt $ 16,326,000

Stockholders_ Equity and Stock-

Stockholders’ Equity and Stock-Based Compensation	9 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
Stockholders’ Equity and Stock-Based Compensation	Stockholders’ Equity and Stock-Based Compensation Follow-on Public Offerings On January 12, 2021, the Company completed an underwritten public offering of 33,368,851 shares of common stock, including 4,352,458 shares of common stock sold pursuant to the underwriters’ exercise in full of their option to purchase additional shares. The price to the public in the offering was $3.05 per share and the underwriters purchased the shares from the Company pursuant to the underwriting agreement at a price of $2.867 per share. The gross proceeds were approximately $101.8 million before deducting underwriting discounts and commissions and other offering expenses of $293,000. On January 25, 2021, the Company completed an underwritten public offering of 38,333,352 shares of common stock, including 5,000,002 shares of common stock sold pursuant to the underwriters’ exercise in full of their option to purchase additional shares. The price to the public in the offering was $6.00 per share and the underwriters purchased the shares from the Company pursuant to the underwriting agreement at a price of $5.64 per share. The gross proceeds were approximately $230.0 million before deducting underwriting discounts and commissions and other offering expenses of $435,000. Shelf Registration Statements; Ladenburg and Cowen At-the-Market Facilities In August 2020, the Company filed a shelf registration statement on Form S-3 with the SEC covering the offering, issuance and sale of up to $125.0 million of the Company’s securities, including up to $40.0 million of common stock pursuant to an At Market Issuance Sales Agreement, with Ladenburg Thalmann & Co. Inc. acting as sales agent (the “Ladenburg ATM”). During October through December 2020, the Company sold 27,025,384 shares of common stock under the Ladenburg ATM at an average share price of $0.82, and received gross proceeds of approximately $22.1 million before deducting offering costs of $573,000. In January 2021, the Company sold an additional 6,298,152 shares of common stock under the ATM at an average share price of $2.68, and received gross proceeds of approximately $16.9 million before deducting offering costs of $422,000. The Company terminated the Ladenburg ATM in March 2021. On January 19, 2021, the Company filed an automatically effective shelf registration statement on Form S-3 with the SEC as a “well-known seasoned issuer,” allowing for the Company to issue an indeterminate number or amount of its securities from time to time in one or more offerings. On March 23, 2021, the Company entered into a Sales Agreement with Cowen and Company, LLC (“Cowen”) which provides for the sale, in the Company’s sole discretion, of shares of common stock having an aggregate offering price of up to $350.0 million through or to Cowen, acting as sales agent or principal (the “Cowen ATM”) . The Company agreed to pay Cowen a commission of up to 3.0% of the aggregate gross proceeds from each sale of shares, reimburse legal fees and disbursements and provide Cowen with customary indemnification and contribution rights. In August and September 2021, the Company sold 2,256,000 shares of common stock under the Cowen ATM at an average share price of $6.15 per share, and received gross proceeds of approximately $13.9 million before deducting offering costs of $0.6 million. Stock Warrants A summary of the Company’s warrant activity during the nine months ended September 30, 2021 was as follows: Shares of Stock under Warrants Weighted- Weighted- Aggregate Outstanding at January 1, 2021 15,174,000 $ 2.34 3.76 $ 26,841,000 Granted — Exercised (10,789,000) 0.89 58,175,000 Canceled (24,000) 3.29 Outstanding at September 30, 2021 4,361,000 $ 5.95 2.02 $ 1,651,000 Stock Options A summary of the Company’s stock option activity during the nine months ended September 30, 2021 was as follows: Shares of Stock under Stock Options Weighted- Weighted- Aggregate Outstanding at January 1, 2021 5,290,000 $ 1.91 8.7 $ 10,178,000 Granted 6,544,000 7.11 Exercised (371,000) 1.49 $ 2,187,000 Canceled (802,000) 4.35 Outstanding at September 30, 2021 10,661,000 $ 4.94 9.01 $ 17,822,000 Vested and exercisable at September 30, 2021 3,035,000 $ 3.31 8.11 $ 9,326,000 For the three months ended September 30, 2021 and 2020, the weighted-average grant date fair value of stock options granted was $3.64 and $0.35 per share, respectively. For the nine months ended September 30, 2021 and 2020, the weighted-average grant date fair value of stock options granted was $4.78 and $0.43 per share, respectively. Stock-Based Compensation The Company recognized stock-based compensation expense for the periods presented as follows: Three Months Ended Nine Months Ended 2021 2020 2021 2020 Research and development $ 745,000 $ 122,000 $ 1,209,000 $ 255,000 General and administrative 2,043,000 325,000 3,708,000 848,000 Total stock-based compensation expense $ 2,788,000 $ 447,000 $ 4,917,000 $ 1,103,000 The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants during the periods presented were as follows: Three Months Ended Nine Months Ended 2021 2020 2021 2020 Risk-free interest rate 0.9 % 0.4 % 1.1 % 0.8 % Expected volatility 71.4 % 77.9 % 78.3 % 74.8 % Expected term (in years) 6.0 5.5 6.0 5.9 Expected dividend yield 0.0 % 0.0 % 0.0 % 0.0 % Restricted Stock Units On May 12, 2021, the compensation committee of the Company’s board of directors granted 580,000 RSUs to R. Erik Holmlin, Ph.D., the Company’s President and Chief Executive Officer (the “Holmlin Grant”), and 240,000 RSUs to Mark Oldakowski, the Company’s Chief Operating Officer (the “Oldakowski Grant”), in each case with an effective grant date and vesting commencement date of May 12, 2021. 290,000 RSUs under the Holmlin Grant are subject to time-based vesting, with 50% of the shares vesting on each of the first and second anniversaries of the vesting commencement date, subject to continued service through the vesting date, and 18 months vesting acceleration upon a termination without cause or resignation with good reason. 290,000 RSUs under the Holmlin Grant are subject to vesting upon the satisfaction of certain specified revenue targets within four years following the vesting commencement date. If Dr. Holmlin’s employment with the Company is terminated without cause or he resigns with good reason, then the shares will continue to be eligible for vesting upon satisfaction of the revenue targets within a period that is the shorter of 18 months following termination or four years following the vesting commencement date. The RSUs comprising the Oldakowski Grant are subject to time-based vesting, with 50% of the shares vesting on each of the first and second anniversaries of the vesting commencement date, subject to continued service through the vesting date.

Litigation

Litigation	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Litigation From time to time, the Company may be subject to potential liabilities under various claims and legal actions that are pending or may be asserted. These matters arise in the ordinary course and conduct of the business. The Company regularly assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in the financial statements. An estimated loss contingency is accrued in the financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Based on the Company’s assessment, it currently does not have any material loss exposure as it is not a defendant in any claims or legal actions.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company is subject to taxation in the United States, United Kingdom and various state jurisdictions. The Company computes its quarterly income tax provision by using a forecasted annual effective tax rate and adjusts for any discrete items arising during the quarter. The primary difference between the effective tax rate and the federal statutory tax rate relates to the full valuation allowance on the Company’s U.S. net operating losses.

Acquisitions

Acquisitions	9 Months Ended
	Sep. 30, 2021
Business Combinations [Abstract]
Acquisitions	Acquisitions Acquisition of Lineagen On August 21, 2020, the Company, Alta Merger Sub, Inc., a wholly owned subsidiary of the Company (“Merger Sub”), Lineagen, a Delaware corporation, and Michael S. Paul, Ph.D., solely in his capacity as exclusive agent and attorney-in-fact of the security-holders of Lineagen, entered into an Agreement and Plan of Merger (the “Merger Agreement”). Pursuant to the terms and conditions of the Merger Agreement, Merger Sub merged with and into Lineagen whereupon the separate corporate existence of Merger Sub ceased, with Lineagen continuing as the surviving corporation of the Merger as a wholly owned subsidiary of the Company. Lineagen’s expertise in development, commercialization and reimbursement of laboratory-developed tests provides a platform for accelerating sales growth for the Company’s Saphyr system. The unaudited pro forma financial information in the table below summarizes the combined results of operations for the Company and Lineagen as if the companies had been combined as of January 1, 2019. The unaudited pro forma financial information is for informational purposes only and is not necessarily indicative of the results of operations that would have been achieved as if the acquisition had taken place as of January 1, 2019. Three Months Ended September 30, Nine Months Ended September 30, (Unaudited) 2020 2020 Revenue $ 3,018,000 $ 7,948,000 Net loss (10,087,000) (30,375,000) Basic and diluted net loss per share $ (0.07) $ (0.33) Acquisition of BioDiscovery On October 8, 2021, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which the Company agreed to acquire BioDiscovery, Inc (“Biodiscovery”). Under the terms of the Merger Agreement,, Bionano purchased 100% of the outstanding shares of BioDiscovery on October 18, 2021. Pursuant to the Merger Agreement, the Company paid upfront consideration consisting of a combination of approximately $50 million in cash and $40 million in shares of Company common stock. The upfront consideration is subject to adjustment for, among other things, cash, unpaid indebtedness, unpaid transaction expenses and working capital relative to a target. Approximately $27 million worth of shares of Company common stock issued as upfront consideration pursuant to the Merger Agreement are subject to vesting based on continued service, subject to the terms and conditions of a stock restriction agreement. Under the Merger Agreement, the Company has also agreed to pay a milestone payment of $10 million in cash based on the achievement of certain commercial milestones. The Merger Agreement has a customary post-closing purchase price adjustment mechanism.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value MeasurementsThe Company holds investment securities that consist of highly liquid, investment grade debt securities. The Company determines the fair value of its investment securities based upon one or more valuations reported by its investment accounting and reporting service provider. The investment service provider values the securities using a hierarchical security pricing model that relies primarily on valuations provided by an industry-recognized valuation service. Such valuations may be based on trade prices in active markets for identical assets or liabilities (Level 1 inputs) or valuation models using inputs that are observable either directly or indirectly (Level 2 inputs), such as quoted prices for similar assets or liabilities, yield curves, volatility factors, credit spreads, default rates, loss severity, current market and contractual prices for the underlying instruments or debt, and broker and dealer quotes, as well as other relevant economic measures. The following table presents the Company’s financial assets and liabilities measured at fair value on a recurring basis in the Unaudited Consolidated Balance Sheets: September 30, 2021 Total Fair Value and Carrying Value on Balance Sheet Fair Value Measurement Category Level 1 Level 2 Level 3 Assets: Commercial Paper $ 97,939,000 $ — $ 97,939,000 $ — Corporate Notes/Bonds $ 87,394,000 $ — $ 87,394,000 $ — Total Investments: $ 185,333,000 $ — $ 185,333,000 $ — Money Market Funds $ 114,331,000 $ 114,331,000 $ — $ — Money Market Funds are classified as cash equivalents on the balance sheet. The Company did not hold any investments as of December 31, 2020. As of September 30, 2021, the Company held 44 securities in an unrealized loss position. None of the Company’s available-for-sale investment securities were in a material unrealized loss position at September 30, 2021. As such, the Company has not recognized any impairment in its financial statements related to its available-for-sale investment securities. As of September 30, 2021, the following table summarizes the amortized cost and the unrealized gains (losses) of the available for sale securities: Commercial Paper Corporate Notes/Bonds Amortized Cost Unrealized gains (losses) Amortized Cost Unrealized gains (losses) Less than 1 year $ 97,957,000 $ (18,000) $ 12,234,000 $ (7,000) Due after one year through five years — — 75,258,000 (91,000) Total $ 97,957,000 $ (18,000) $ 87,492,000 $ (98,000) Included in interest income for the three-month period ended September 30, 2021 was interest income related to the Company’s available for sale securities of $13,000. All interest income related to the available for sale securities in 2021 related to three-month period ended September 30, 2021. All available-for-sale securities are classified as current assets, even if the maturity when acquired by the Company is greater than one year due to the ability to liquidate within the next 12 months.

Organization and Basis of Pre_2

Organization and Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of PresentationThe accompanying financial information has been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim reporting purposes. The condensed consolidated financial statements are unaudited. The unaudited condensed consolidated financial statements reflect, in the opinion of the Company’s management, all adjustments, consisting of only normal recurring adjustments, necessary for a fair presentation of financial position, results of operations, changes in equity, and comprehensive loss and cash flows for each period presented in accordance with United States generally accepted accounting principles (“U.S. GAAP”). All intercompany transactions and balances have been eliminated. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.
Liquidity	Liquidity As of September 30, 2021, the Company had approximately $140.7 million in cash and cash equivalents, $185.3 million in available-for-sale investment securities, and working capital of $324.3 million as a result of common stock offerings executed in the quarters ended December 31, 2020, March 31, 2021, and September 30, 2021. In February 2021, we applied for forgiveness of our Paycheck Protection Program Loan of approximately $1.8 million (“the PPP Loan”) , and in March 2021, the PPP Loan, including all accrued interest, was forgiven in full. During the previous quarter ended June 30, 2021, the outstanding term loan with Innovatus (as defined below) was paid in full, including all accrued interest, an end of term fee, and a prepayment fee for a total of $17.0 million.
Fair Value Measurements	Fair Value Measurements The Company measures certain financial assets and liabilities at fair value on a recurring basis. Fair value is the price the Company would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date. ASC 820, “Fair Value Measurements and Disclosures”, defines and establishes a framework for measuring fair value and expands disclosures about fair value measurements. In accordance with ASC 820, the Company has categorized its financial assets and liabilities, based on the priority of the inputs to the valuation technique, into a three-level fair value hierarchy as set forth below. Level 1 – Assets and liabilities whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market that the company has the ability to access at the measurement date. Level 2 – Assets and liabilities whose values are based on quoted prices for similar attributes in active markets; quoted prices in markets where trading occurs infrequently; and inputs other than quoted prices that are observable, either directly or indirectly, for substantially the full term of the asset or liability. Level 3 – Assets and liabilities whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. If the inputs used to measure the financial instruments fall within different levels of the hierarchy, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.
Investment securities	Investment Securities All investments have been classified as “available-for-sale” and are carried at fair value as determined based upon quoted market prices or pricing models for similar securities at period end. Investments with contractual maturities less than 12 months at the balance sheet date are considered short-term investments. Investments with contractual maturities beyond one year are also classified as short-term due to the Company’s ability to liquidate the investment for use in operations within the next 12 months. Realized gains and losses on investment securities are included in earnings and are derived using the specific identification method for determining the cost of securities sold. The Company has not realized any significant gains or losses on sales of available-for-sale investment securities during any of the periods presented. As all the Company’s investment holdings are in the form of debt securities, unrealized gains and losses that are determined to be temporary in nature are reported as a component of accumulated other comprehensive income (loss). A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the establishment of a new cost basis for the security. Interest income is recognized when earned, as are the amortization of purchase premiums and accretion of purchase discounts on investment securities.
Recently Issued But Not Yet Adopted Accounting Pronouncements	Recently Issued But Not Yet Adopted Accounting Pronouncements In February 2015, the FASB issued Accounting Standards Update (“ASU”) 2016-2, Leases (Topic 842) , which amends the accounting guidance for leases and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about leasing arrangements. ASU 2016-2 initially mandated a modified retrospective transition method, however, in July 2018, the FASB issued ASU 2018-11, Leases (Topic 842): Targeted Improvements, which amends ASU 2016-2, permitting entities the option to adopt this standard prospectively with a cumulative-effect adjustment to opening equity in the year of adoption and include required disclosures for prior periods but will not restate prior periods. The Company anticipates implementing the accounting guidance for leases using the alternative method beginning with the annual reporting period ending December 31, 2021 and interim reporting periods in 2022. The Company is in the process of evaluating the impact of adoption of the lease accounting guidance on the consolidated financial statements. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses: Measurement of credit Losses on Financial Instruments (ASU 2016-13) , which amends the impairment model by requiring entities to use a forward looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available-for-sale debt securities. The standard is effective for the company beginning in the first quarter of 2023, with early adoption permitted. The Company is currently evaluating the expected impact of ASU 2016-13 on its financial statements. In May 2021, the FASB issued ASU No. 2021-04, Issuer’s Accounting for Certain Modifications or Exchanges for Freestanding Equity-Classified Written Call Options to clarify the accounting for modifications or exchanges of equity- classified warrants.The standard is effective for fiscal years beginning after December 15, 2021. Early adoption is permitted. The Company is in the process of evaluating the expected impact of ASU 2021-04
Net Loss Per Share	Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common share equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. The Company’s potentially dilutive securities which include warrants, outstanding stock options, and Restricted Stock Units (“RSUs”) under the Company’s equity incentive plan have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding.

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss Per Share Attributable to Common Stockholders	Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares): September 30, September 30, Stock options 10,661,000 5,331,000 Warrants 4,361,000 29,709,000 RSUs 820,000 — Total 15,842,000 35,040,000

Revenue Recognition (Tables)

Revenue Recognition (Tables)	9 Months Ended
	Sep. 30, 2021
Revenue from Contract with Customer [Abstract]
Schedule of Revenue Recognition	Revenue by Source Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Instruments $ 1,468,000 $ 724,000 $ 3,507,000 $ 1,487,000 Consumables 1,832,000 856,000 4,338,000 2,016,000 Total product revenue 3,300,000 1,580,000 7,845,000 3,503,000 Service and other 1,355,000 616,000 3,834,000 1,010,000 Total revenue $ 4,655,000 $ 2,196,000 $ 11,679,000 $ 4,513,000 Revenue by Geographic Location Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 $ % $ % $ % $ % North America $ 2,557,000 55 % $ 874,000 40 % $ 6,419,000 55 % $ 2,388,000 53 % EMEIA 1,234,000 27 % 1,204,000 55 % 3,762,000 32 % 1,908,000 42 % Asia Pacific 864,000 18 % 118,000 5 % 1,498,000 13 % 217,000 5 % Total $ 4,655,000 100 % $ 2,196,000 100 % $ 11,679,000 100 % $ 4,513,000 100 %

Balance Sheet Account Details (

Balance Sheet Account Details (Tables)	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Accounts Receivable	September 30, December 31, Accounts receivable, net: Accounts receivable, trade $ 5,011,000 $ 4,894,000 Less allowance for doubtful accounts (2,015,000) (2,119,000) $ 2,996,000 $ 2,775,000
Schedule of Components of Inventories	The components of inventories are as follows: September 30, December 31, Inventory: Raw materials $ 1,024,000 $ 2,283,000 Finished goods 7,996,000 1,033,000 $ 9,020,000 $ 3,316,000

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Schedule of Debt	The carrying value of the Company’s debt as of December 31, 2020 was as follows: December 31, Term Loans $ 15,981,000 PPP Loan 1,775,000 Total principal 17,756,000 Less unamortized debt issuance costs (1,430,000) Total carrying value of debt $ 16,326,000

Stockholders_ Equity and Stoc_2

Stockholders’ Equity and Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
Schedule of Warrant Activity	A summary of the Company’s warrant activity during the nine months ended September 30, 2021 was as follows: Shares of Stock under Warrants Weighted- Weighted- Aggregate Outstanding at January 1, 2021 15,174,000 $ 2.34 3.76 $ 26,841,000 Granted — Exercised (10,789,000) 0.89 58,175,000 Canceled (24,000) 3.29 Outstanding at September 30, 2021 4,361,000 $ 5.95 2.02 $ 1,651,000
Summary of Stock Option Activity	A summary of the Company’s stock option activity during the nine months ended September 30, 2021 was as follows: Shares of Stock under Stock Options Weighted- Weighted- Aggregate Outstanding at January 1, 2021 5,290,000 $ 1.91 8.7 $ 10,178,000 Granted 6,544,000 7.11 Exercised (371,000) 1.49 $ 2,187,000 Canceled (802,000) 4.35 Outstanding at September 30, 2021 10,661,000 $ 4.94 9.01 $ 17,822,000 Vested and exercisable at September 30, 2021 3,035,000 $ 3.31 8.11 $ 9,326,000
Summary of Recognized Stock-Based Compensation Expense	The Company recognized stock-based compensation expense for the periods presented as follows: Three Months Ended Nine Months Ended 2021 2020 2021 2020 Research and development $ 745,000 $ 122,000 $ 1,209,000 $ 255,000 General and administrative 2,043,000 325,000 3,708,000 848,000 Total stock-based compensation expense $ 2,788,000 $ 447,000 $ 4,917,000 $ 1,103,000
Schedule of Weighted-Average Assumptions in Black -Scholes Option Pricing Model	The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants during the periods presented were as follows: Three Months Ended Nine Months Ended 2021 2020 2021 2020 Risk-free interest rate 0.9 % 0.4 % 1.1 % 0.8 % Expected volatility 71.4 % 77.9 % 78.3 % 74.8 % Expected term (in years) 6.0 5.5 6.0 5.9 Expected dividend yield 0.0 % 0.0 % 0.0 % 0.0 %

Acquisitions (Tables)

Acquisitions (Tables)	9 Months Ended
	Sep. 30, 2021
Business Combinations [Abstract]
Business Acquisition, Pro Forma Information	The unaudited pro forma financial information is for informational purposes only and is not necessarily indicative of the results of operations that would have been achieved as if the acquisition had taken place as of January 1, 2019. Three Months Ended September 30, Nine Months Ended September 30, (Unaudited) 2020 2020 Revenue $ 3,018,000 $ 7,948,000 Net loss (10,087,000) (30,375,000) Basic and diluted net loss per share $ (0.07) $ (0.33)

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table presents the Company’s financial assets and liabilities measured at fair value on a recurring basis in the Unaudited Consolidated Balance Sheets: September 30, 2021 Total Fair Value and Carrying Value on Balance Sheet Fair Value Measurement Category Level 1 Level 2 Level 3 Assets: Commercial Paper $ 97,939,000 $ — $ 97,939,000 $ — Corporate Notes/Bonds $ 87,394,000 $ — $ 87,394,000 $ — Total Investments: $ 185,333,000 $ — $ 185,333,000 $ — Money Market Funds $ 114,331,000 $ 114,331,000 $ — $ —
Marketable Securities	As of September 30, 2021, the following table summarizes the amortized cost and the unrealized gains (losses) of the available for sale securities: Commercial Paper Corporate Notes/Bonds Amortized Cost Unrealized gains (losses) Amortized Cost Unrealized gains (losses) Less than 1 year $ 97,957,000 $ (18,000) $ 12,234,000 $ (7,000) Due after one year through five years — — 75,258,000 (91,000) Total $ 97,957,000 $ (18,000) $ 87,492,000 $ (98,000)

Organization and Basis of Pre_3

Organization and Basis of Presentation (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Mar. 31, 2021	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and cash equivalents		$ 140,736		$ 140,736		$ 38,449
Investments		185,333		185,333		$ 0
Working capital		324,300		324,300
Gain on forgiveness of PPP Loan	$ 1,800	$ 0	$ 0	1,775	$ 0
Repayments of debt				$ 17,010	$ 5,000

Net Loss Per Share (Details)

Net Loss Per Share (Details) - shares shares in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount (in shares)	15,842	35,040
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount (in shares)	10,661	5,331
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount (in shares)	4,361	29,709
RSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount (in shares)	820	0

Revenue Recognition - Revenue b

Revenue Recognition - Revenue by Source and Geographic Location (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Disaggregation of Revenue [Line Items]
Revenue	$ 4,655	$ 2,196	$ 11,679	$ 4,513
North America
Disaggregation of Revenue [Line Items]
Revenue	2,557	874	6,419	2,388
EMEIA
Disaggregation of Revenue [Line Items]
Revenue	1,234	1,204	3,762	1,908
Asia Pacific
Disaggregation of Revenue [Line Items]
Revenue	$ 864	$ 118	$ 1,498	$ 217
Revenue from Contract with Customer | Geographic Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk percentage	100.00%	100.00%	100.00%	100.00%
Revenue from Contract with Customer | Geographic Concentration Risk | North America
Disaggregation of Revenue [Line Items]
Concentration risk percentage	55.00%	40.00%	55.00%	53.00%
Revenue from Contract with Customer | Geographic Concentration Risk | EMEIA
Disaggregation of Revenue [Line Items]
Concentration risk percentage	27.00%	55.00%	32.00%	42.00%
Revenue from Contract with Customer | Geographic Concentration Risk | Asia Pacific
Disaggregation of Revenue [Line Items]
Concentration risk percentage	18.00%	5.00%	13.00%	5.00%
Product revenue
Disaggregation of Revenue [Line Items]
Revenue	$ 3,300	$ 1,580	$ 7,845	$ 3,503
Instruments
Disaggregation of Revenue [Line Items]
Revenue	1,468	724	3,507	1,487
Consumables
Disaggregation of Revenue [Line Items]
Revenue	1,832	856	4,338	2,016
Service and other revenue
Disaggregation of Revenue [Line Items]
Revenue	$ 1,355	$ 616	$ 3,834	$ 1,010

Revenue Recognition - Narrative

Revenue Recognition - Narrative (Details) - Geographic Concentration Risk - Revenue Benchmark	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
United States
Disaggregation of Revenue [Line Items]
Concentration risk percentage	44.20%	40.00%	50.00%	51.00%
China
Disaggregation of Revenue [Line Items]
Concentration risk percentage	17.90%
CANADA
Disaggregation of Revenue [Line Items]
Concentration risk percentage	10.80%

Revenue Recognition - Remaining

Revenue Recognition - Remaining Performance Obligations (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligation	$ 569		$ 569
Revenue recognized	$ 79	$ 66	$ 326	$ 299
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-10-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligation, percentage	30.70%		30.70%
Timing of satisfaction of remaining performance obligation	3 months		3 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligation, percentage	49.90%		49.90%
Timing of satisfaction of remaining performance obligation	1 year		1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligation, percentage	19.50%		19.50%
Timing of satisfaction of remaining performance obligation	1 year		1 year

Balance Sheet Account Details -

Balance Sheet Account Details - Schedule of Accounts Receivable (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accounts receivable, trade	$ 5,011	$ 4,894
Less allowance for doubtful accounts	(2,015)	(2,119)
Accounts receivable, net	$ 2,996	$ 2,775

Balance Sheet Account Details_2

Balance Sheet Account Details - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2021	Dec. 31, 2020
Product Information [Line Items]
Accounts receivable	$ 2,996	$ 2,996	$ 2,775
Recovery of bad debt expense	(10)	(50)
Lineagen
Product Information [Line Items]
Accounts receivable	$ 680	$ 680
Two Customers | Accounts Receivable | Customer Concentration Risk
Product Information [Line Items]
Concentration risk percentage			27.40%

Balance Sheet Account Details_3

Balance Sheet Account Details - Schedule of Components of Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials	$ 1,024	$ 2,283
Finished goods	7,996	1,033
Inventory, net	$ 9,020	$ 3,316

Debt - Narrative (Details)

Debt - Narrative (Details) - USD ($)	Apr. 17, 2020	Mar. 31, 2021	Mar. 31, 2019	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	May 14, 2021
Debt Instrument [Line Items]
Gain on forgiveness of PPP Loan		$ 1,800,000		$ 0	$ 0	$ 1,775,000	$ 0
Repayments of debt						17,010,000	$ 5,000,000
Loan Under Paycheck Protection Program | Unsecured Loan
Debt Instrument [Line Items]
Proceeds from issuance of debt	$ 1,800,000
Gain on forgiveness of PPP Loan						$ 1,800,000
Term A-1 Loan
Debt Instrument [Line Items]
Term loan face value			$ 17,500,000
Term A-2 Loan
Debt Instrument [Line Items]
Term loan face value			2,500,000
Innovatus Term 3 Loan
Debt Instrument [Line Items]
Term loan face value			$ 5,000,000
Innovatus LSA
Debt Instrument [Line Items]
Cash rate			10.25%
Discounted cash rate			7.25%
Effective interest rate								16.70%
End of term fee			$ 800,000
Innovatus LSA | Period One
Debt Instrument [Line Items]
Prepayment fee percentage			3.00%
Innovatus LSA | Period Two
Debt Instrument [Line Items]
Prepayment fee percentage			2.00%
Innovatus LSA | Period Three
Debt Instrument [Line Items]
Prepayment fee percentage			1.00%
Innovatus LSA | Period Four
Debt Instrument [Line Items]
Prepayment fee percentage			0.00%
Innovatus LSA | PIK
Debt Instrument [Line Items]
Cash rate			3.00%
Revolver
Debt Instrument [Line Items]
Term loan facility available			$ 5,000,000

Debt - Schedule of Debt (Detail

Debt - Schedule of Debt (Details) $ in Thousands	Dec. 31, 2020USD ($)
Debt Instrument [Line Items]
Total principal	$ 17,756
Less unamortized debt issuance costs	(1,430)
Total carrying value of debt	16,326
Term Loans
Debt Instrument [Line Items]
Total principal	15,981
PPP Loan
Debt Instrument [Line Items]
Total principal	$ 1,775

Stockholders_ Equity and Stoc_3

Stockholders’ Equity and Stock-Based Compensation - Narrative (Details) - USD ($)	May 12, 2021	Mar. 23, 2021	Jan. 25, 2021	Jan. 12, 2021	Jan. 31, 2021	Sep. 30, 2021	Dec. 31, 2020	Aug. 31, 2020
Class of Stock [Line Items]
Number of shares issued (in shares)			38,333,352	33,368,851	6,298,152	2,256,000	27,025,384
Average share price (in dollars per share)			$ 6	$ 3.05	$ 2.68	$ 6.15	$ 0.82
Gross proceeds			$ 230,000,000	$ 101,800,000	$ 16,900,000	$ 13,900,000	$ 22,100,000
Offering costs			$ 435,000	$ 293,000	$ 422,000	$ 600,000	$ 573,000
Authorized amount of stock to be issued								$ 125,000,000
RSUs | R. Erik Holmlin
Class of Stock [Line Items]
Units granted (in shares)	580,000
RSUs | R. Erik Holmlin | Time-Based Vesting
Class of Stock [Line Items]
Units granted (in shares)	290,000
Percentage of shares vesting on the first and second anniversary	50.00%
Vesting period, termination of employment	18 months
RSUs | R. Erik Holmlin | Performance Satisfaction Vesting
Class of Stock [Line Items]
Units granted (in shares)	290,000
RSUs | R. Erik Holmlin | Performance Satisfaction Vesting | Maximum
Class of Stock [Line Items]
Vesting period, termination of employment	4 years
RSUs | R. Erik Holmlin | Performance Satisfaction Vesting | Minimum
Class of Stock [Line Items]
Vesting period, termination of employment	18 months
RSUs | Mark Oldakowski
Class of Stock [Line Items]
Units granted (in shares)	240,000
RSUs | Mark Oldakowski | Time-Based Vesting
Class of Stock [Line Items]
Percentage of shares vesting on the first and second anniversary	50.00%
Cowen
Class of Stock [Line Items]
Aggregate offering price		$ 350,000,000
Commission fee		3.00%
Over-Allotment Option
Class of Stock [Line Items]
Number of shares issued (in shares)			5,000,002	4,352,458
Average share price (in dollars per share)			$ 5.64	$ 2.867
Common Stock
Class of Stock [Line Items]
Authorized amount of stock to be issued								$ 40,000,000

Stockholders_ Equity and Stoc_4

Stockholders’ Equity and Stock-Based Compensation - Warrant Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Shares of Stock under Warrants
Beginning balance (in shares)	15,174
Granted (in shares)	0
Exercised (in shares)	(10,789)
Canceled (in shares)	(24)
Ending balance (in shares)	4,361	15,174
Weighted- Average Exercise Price
Beginning balance (in USD per share)	$ 2.34
Exercised (in USD per share)	0.89
Cancelled (in dollars per share)	3.29
Ending balance (in USD per share)	$ 5.95	$ 2.34
Weighted- Average Remaining Contractual Term
Balance	2 years 7 days	3 years 9 months 3 days
Aggregate Intrinsic Value
Beginning balance	$ 26,841
Exercised	58,175
Ending balance	$ 1,651	$ 26,841

Stockholders_ Equity and Stoc_5

Stockholders’ Equity and Stock-Based Compensation - Summary of Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Shares of Stock under Stock Options
Beginning balance (in shares)			5,290
Granted (in shares)			6,544
Exercised (in shares)			(371)
Canceled (in shares)			(802)
Ending balance (in shares)	10,661		10,661		5,290
Vested and exercisable (in shares)	3,035		3,035
Weighted- Average Exercise Price
Beginning balance (in USD per share)			$ 1.91
Granted (in USD per share)			7.11
Exercised (in USD per share)			1.49
Canceled (in USD per share)			4.35
Ending balance (in USD per share)	$ 4.94		4.94		$ 1.91
Vested and exercisable (in USD per share)	$ 3.31		$ 3.31
Weighted- Average Remaining Contractual Term
Outstanding (in years)			9 years 3 days		8 years 8 months 12 days
Vested and exercisable (in years)			8 years 1 month 9 days
Aggregate Intrinsic Value
Beginning balance			$ 10,178
Exercised			2,187
Ending balance	$ 17,822		17,822		$ 10,178
Vested and exercisable	$ 9,326		$ 9,326
Weighted-average grant date fair value (in USD per share)	$ 3.64	$ 0.35	$ 4.78	$ 0.43

Stockholders_ Equity and Stoc_6

Stockholders’ Equity and Stock-Based Compensation - Recognized Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
General and administrative	$ 2,788	$ 447	$ 4,917	$ 1,103
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
General and administrative	745	122	1,209	255
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
General and administrative	$ 2,043	$ 325	$ 3,708	$ 848

Stockholders_ Equity and Stoc_7

Stockholders’ Equity and Stock-Based Compensation - Assumptions (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share-based Payment Arrangement [Abstract]
Risk-free interest rate	0.90%	0.40%	1.10%	0.80%
Expected volatility	71.40%	77.90%	78.30%	74.80%
Expected term (in years)	6 years	5 years 6 months	6 years	5 years 10 months 24 days
Expected dividend yield	0.00%	0.00%	0.00%	0.00%

Acquisitions - Pro Forma Inform

Acquisitions - Pro Forma Information (Details) - Lineagen - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2021
Business Acquisition [Line Items]
Revenue	$ 3,018	$ 7,948
Net loss	$ (10,087)	$ (30,375)
Basic net loss per share (in dollars per share)	$ (0.07)	$ (0.33)
Diluted net loss per share (in dollars per share)	$ (0.07)	$ (0.33)

Acquisitions - Narrative (Detai

Acquisitions - Narrative (Details) - BioDiscovery - Subsequent Event $ in Millions	Oct. 08, 2021USD ($)
Business Acquisition [Line Items]
Acquired shares purchased (in shares)	100.00%
Consideration transferred, cash	$ 50
Consideration transferred, value of shares	40
Consideration transferred, value of shares subject to vesting	27
Business Acquisition, Milestone Payment	$ 10

Fair Value Measurements - Finan

Fair Value Measurements - Financial Assets and Liabilities (Details) - Fair Value, Recurring $ in Thousands	Sep. 30, 2021USD ($)
Total Investments
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	$ 185,333
Total Investments | Commercial Paper
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	97,939
Total Investments | Corporate Notes/Bonds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	87,394
Money Market Funds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	114,331
Level 1 | Total Investments
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0
Level 1 | Total Investments | Commercial Paper
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0
Level 1 | Total Investments | Corporate Notes/Bonds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0
Level 1 | Money Market Funds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	114,331
Level 2 | Total Investments
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	185,333
Level 2 | Total Investments | Commercial Paper
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	97,939
Level 2 | Total Investments | Corporate Notes/Bonds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	87,394
Level 2 | Money Market Funds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0
Level 3 | Total Investments
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0
Level 3 | Total Investments | Commercial Paper
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0
Level 3 | Total Investments | Corporate Notes/Bonds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0
Level 3 | Money Market Funds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	$ 0

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) $ in Thousands	3 Months Ended
	Sep. 30, 2021USD ($)security
Fair Value Disclosures [Abstract]
Number of securities in an unrealized loss position | security	44
Interest income | $	$ 13

Fair Value Measurements - Amort

Fair Value Measurements - Amortized Cost and Unrealized Gains (Losses) (Details) $ in Thousands	Sep. 30, 2021USD ($)
Commercial Paper
Amortized Cost
Less than 1 year	$ 97,957
Due after one year through five years	0
Total	97,957
Unrealized gains (losses)
Less than 1 year	(18)
Due after one year through five years	0
Total	(18)
Corporate Notes/Bonds
Amortized Cost
Less than 1 year	12,234
Due after one year through five years	75,258
Total	87,492
Unrealized gains (losses)
Less than 1 year	(7)
Due after one year through five years	(91)
Total	$ (98)